Replies to post #137089 on Biotech Values

[biomaven0]

113 phase 2 would be comprised of crizotinib failures?

No, based on this paper only about 1/4 of crizotinib failures would likely be helped by '113. But you might be able to tell ahead of time which might be helped though, in which case the Phase II could be a subset of crizotinib failures.

If '113 works for EGFR failures, that is actually a significantly bigger market than ALK.

Ideally you'd like to get some crizotnib-naive ALK patients exposed to the drug, but that would have to come later in the process.

Peter